AstraZeneca amends license deal with Chinese biotech; Chinese protein-based vaccine gets manufacturing OK
In an effort to boost the supply of its AAV Covid-19 vaccine abroad, AstraZeneca has amended its license agreement with Biokangtai to commercialize the drug …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
